FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AARTIDRUGS

1,255.85
-20.4 (-1.6%)
Updated 03:28 02/07 IST

AARTIDRUGS Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for AARTIDRUGS
Disclaimer
0% Bullish
0% Bearish

AARTIDRUGS Buy or Sell - Brokerage Reports

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
796
Consensus Potential
-60.33%
See AARTIDRUGS Share Price Targets >>

AARTIDRUGS Ratings

Long term AARTIDRUGS rating by FrontPage users
5/5 (1 Ratings)
Find answers to all your questions on live AARTIDRUGS message board: Is AARTIDRUGS buy or sell? Should I buy AARTIDRUGS shares? Why are AARTIDRUGS shares falling? Should I invest in AARTIDRUGS stock?

  1. Home
  2. AARTIDRUGS Forum

AARTIDRUGS Share Price Discussion


Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹1,299.95
Price@Trade
₹1,299.95
Target Price
₹1,350
Stop Price
₹1,260
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹259,990 approx for 200 Qty
Status
Active
Like
Reply
N
Reputation: 3,757 • Jun 4 4:41 AM
Share market update: 20 stocks hit 52-week highs on NSE
The BSE Sensex was trading 52.72 points down at 34056.82.
The Economic Times
Like
Reply
N
Reputation: 3,757 • Jun 3 8:03 AM
Midcaps may take time to catch-up; 12 names to bet on amid uncertainty
While the large-cap stocks have been rising, experts believe as sectors, mid-caps and small-caps will take a longer time to pick up as bigger companies could be in a better position to grab higher market share in their respective sectors after the lockdown ends.
Moneycontrol
Like
Reply
S
Reputation: 3,971 • May 29 5:39 AM

Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹984
Price@Trade
₹984
Target Price
₹1,086
Stop Price
₹958
Valid Till
Jun 1, 2020 3:20 AM
Margin
₹787,200 approx for 800 Qty
Status
Exited
Exit Price
₹984.7
Net P&L
+₹560 (+0.07%)
Like
Reply (1)
Latest replies
Sam Sir @samsirs
May 29 5:45 AM

Update
Exited
Exit Price
₹984.7
Net P&L
+₹560 (+0.07%)

AARTIDRUGS - chart - 834607
#AARTIDRUGS BUY TRIGGERED TARGET 981/1122 SUPPORT SL 770
Like
Reply
Like
Reply
N
Reputation: 3,757 • May 21 3:03 AM
Aarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,757 • May 20 9:58 AM
Buy Aarti Drugs; target of Rs 1028: Anand Rathi
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 1028 in its research report dated May 19, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,757 • May 18 7:03 AM
Aarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-Y
Moneycontrol
Like
Reply

Aarti Drugs - Q4 FY20 (Audited –Cons)
CMP: 861
Total income from operations at 449.6 Cr
459.1 Cr (-2.11%) YoY | 473.5 Cr (-5.07%) QoQ
Year ending revenue: 1,806 Cr Vs. 1,560 Cr (15.71%)
Net Profit of 58.8 Cr
27.4 Cr (114.61%) YoY 27.7 Cr (114.92%...
Read more...
4
Reply
C
Reputation: 190 • May 15 3:54 AM
Post by ChartArt in AARTIDRUGS community on FrontPage
#ChartArt #EducationalPurposes #AARTIDRUGS #NIFTY50 #NIFTYBANK Good confluence breakout at current level CMP 835 LOOKING BULLISH
FrontPage
Like
Reply

AARTIDRUGS - chart - 794765
#AARTIDRUGS Long Term Range Breakout.
If This Breakout IS Real And Not a False One then We can Expect A Minimum Move till 1000 And Beyond.
(This Chart Is Also Useful For An Investor).
7
Reply

Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹842  ₹843.05
Price@Trade
₹844.85
Target Price
₹915
Stop Price
₹780
Valid Till
May 21, 2020 3:20 AM
Margin
₹42,152.5 approx for 50 Qty
Status
Exited
Exit Price
₹859.9
Net P&L
+₹842.5 (+2%)
Like
Reply (3)
Latest replies

Update
Entry Price Modified
Price @ Update
₹843.05
Original Entry Price
₹842
New Entry Price
₹843.05
TrackerBot @trackerbot
May 14 8:54 AM

Update
Trade Entered
Entry Price
₹843.05

Update
Exited
Exit Price
₹859.9
Net P&L
+₹842.5 (+2%)
S
Reputation: 3,971 • May 14 8:50 AM

Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹843
Price@Trade
₹844.65
Target Price
₹860
Stop Price
₹840
Valid Till
May 15, 2020 3:20 AM
Margin
₹84,300 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹840
Net P&L
-₹300 (-0.36%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
May 14 8:52 AM

Update
Trade Entered
Entry Price
₹843
TrackerBot @trackerbot
May 14 8:52 AM

Update
Stoploss Hit
Exit Price
₹840
C
Reputation: 190 • May 14 8:47 AM

AARTIDRUGS - chart - 793236
#ChartArt #EducationalPurposes #AARTIDRUGS #NIFTY50 #NIFTYBANK
Good confluence breakout at current level CMP 835 LOOKING BULLISH
Like
Reply
T
Reputation: -540 • Apr 27 5:28 AM

AARTIDRUGS - chart - 742811
(TMT) AARTI DRUGS LTD. (740.35):- AS PER CHART NEAR TO RESISTANCE ZONE, ENTER AT CMP SUPPORT 720-700, FIRST HURDLE AT 800 AND CROSS AND CLOSE ABOVE THEN POSSIBLE 1000+
Like
Reply
N
Reputation: 3,757 • Feb 24 7:43 AM
Brokerages see Sensex around 43,650 in a year; top investment ideas post Q3
Prabhudas Lilladher also revised its 12-month Nifty target to 13,461 (against 13,306 earlier), saying the Nifty gains would be a function of economic revival and fallout of coronavirus.
Moneycontrol
Like
Reply
N
Reputation: 3,757 • Feb 24 7:38 AM
Brokerages see Nifty around 13,350 & Sensex around 43,650 in a year; 10 investment ideas
Prabhudas Lilladher also revised its 12-month Nifty target to 13,461 (against 13,306 earlier), saying the Nifty gains would be a function of economic revival and fallout of coronavirus.
Moneycontrol
Like
Reply
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AARTIDRUGS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,510.18
    Enterprise Value1,947.33
    Price to Earnings16.37
    Price to Book Value2.91
    Return on Capital Employed0.15
    Return on Equity0.17
    Face Value10
    Dividend YieldNA
  • AARTIDRUGS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-Jun-19AnandRathiBuy796
    4-Oct-18CentrumBuy910
    14-Jun-18AnandRathiBuy720
    15-Jan-18CentrumBuy940
    AARTIDRUGS Brokerage Price Target
  • AARTIDRUGS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 21279.65128912401259.1
    Jul 11271.951305.3512701276.25
    Jun 3012851303.41260.051270.55
    Jun 29128112821250.051269.6
    Jun 261189.813001189.81282.75
  • AARTIDRUGS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,105.01
    30 Day Moving Average₹1,045.51
    50 Day Moving Average₹927.28
    100 Day Moving Average₹764.23
    200 Day Moving Average₹642.24
  • AARTIDRUGS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,1401,092.260.04
    Operating Profit185181.280.02
    Profit Before Tax112106.540.05
    Net Income7374.24-0.02
  • AARTIDRUGS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds5194320.2
    Total Liabilities862881-0.02
    Total Assets1,3801,3140.05
  • AARTIDRUGS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity61174.21-0.65
    Cash from Investing Activity-71-96.29-0.26
    Cash from Financing Activity9-78.42-1.11
    Net Cash FlowNA-0.5-1
  • AARTIDRUGS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.07
    Return on Equity0.170.19
    Return on Capital Employed0.150.17
  • AARTIDRUGS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.05
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.06
    3 Year CAGR Growth in Net Income-0.06
    3 Yr CAGR Growth - Diluted EPS-0.03
  • AARTIDRUGS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.38
    5 Year CAGR Growth in Operating Profit0.5
    5 Year CAGR Growth in EBIDTA0.5
    5 Year CAGR Growth in Net Income0.61
    3 Yr CAGR Growth - Diluted EPS-0.17
  • AARTIDRUGS - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 4 4:41 AM
    Share market update: 20 stocks hit 52-week highs on NSE
    The Economic Times
    NewsBot
    Jun 3 8:03 AM
    Midcaps may take time to catch-up; 12 names to bet on amid uncertainty
    Moneycontrol
    NewsBot
    May 21 3:03 AM
    Aarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-Y
    Moneycontrol
    NewsBot
    May 20 9:58 AM
    Buy Aarti Drugs; target of Rs 1028: Anand Rathi
    Moneycontrol
    NewsBot
    May 18 7:03 AM
    Aarti Drugs Consolidated March 2020 Net Sales at Rs 449.64 crore, down 2.07% Y-o-Y
    Moneycontrol
    NewsBot
    Feb 24 7:43 AM
    Brokerages see Sensex around 43,650 in a year; top investment ideas post Q3
    Moneycontrol
    NewsBot
    Feb 24 7:38 AM
    Brokerages see Nifty around 13,350 & Sensex around 43,650 in a year; 10 investment ideas
    Moneycontrol
    NewsBot
    Oct 24, 2019 9:18 AM
    Aarti Drugs Consolidated September 2019 Net Sales at Rs 477.50 crore, up 37.45% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 29, 2019 2:13 AM
    Stocks in the news: ICICI Bank, Cadila Health, Mahindra Life, Vedanta, Uflex, Granules, NHPC
    moneycontrol.com
    NewsBot
    Jul 29, 2019 1:18 AM
    Stocks in the news: ICICI Bank, Cadila Health, Mahindra Life, Vedanta, Uflex, Granules India
    www.moneycontrol.com
  • AARTIDRUGS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020